KAMILLA Trial Shows Practice-Changing Safety/Efficacy for HER2+ mBC
Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the clinical implications of the results of the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
According to Wuerstein, KAMILLA has confirmed the safety and efficacy of T-DM1 in HER2+ breast cancer. Additionally, the study did not find any new safety signals. The secondary end points of the study looked at several secondary end points of note, but no new safety signals were found.
T-DM1 isn’t just used in metastatic breast cancer, as it is moving into post-neoadjuvant treatment space. According to Wuerstein, this impacts the clinical space as it offers care providers a new treatment option for this patient population.
T-DXd Shows Effectiveness in Treating HER2+ Advanced Solid Tumors
April 1st 2024The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.
Read More
Challenges Persist for HCPs and Patients With Breast Cancer
March 1st 2024In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.
Read More
